Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2/3. fázis

Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

A legfontosabb adatok

Ki végzi
University College, London
Hol
Egyesült Királyság25 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
2/3. fázis
Résztvevők
148 fő, tervezett
Kezdés
2020. febr. 3.
Várható befejezés
2030. márc.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Dexamethasone, cyclophosphamide, rituximab
  • Rituximab, ibrutinib
A regiszteradat frissítve
2024. május 10.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 31 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients ≥ 18 years
  • Confirmed diagnosis of WM (according to consensus panel / WHO criteria) with measurable IgM paraprotein
  • Previously untreated disease at any stage requiring therapy at the discretion of the treating physician. Suggested criteria for initiating treatment include:; haematological suppression to Hb <10g/dl, or neutrophils <1.5x109/l or platelets <150x109/l; clinical evidence of hyperviscosity; bulky lymphadenopathy and/or bulky splenomegaly; presence of B symptoms
  • No previous chemotherapy (prior plasma exchange and steroids are permissible)
  • Eastern Cooperative Oncology Group (ECOG) performance status grade 0 - 2
  • Life expectancy of greater than 6 months
  • Written informed consent
  • Willing to comply with the contraceptive requirements of the trial
  • Negative serum or urine pregnancy test for women of childbearing potential (WOCBP)

Ki nem vehet részt

  • Prior therapy for WM
  • Major surgery within 4 weeks prior to randomisation
  • Clinically significant cardiac disease including the following:; Myocardial infarction within 6 months prior to randomisation; Unstable angina within 3 months prior to randomisation; New York Heart Association class III or IV congestive heart failure; History of clinically significant arrhythmias (e.g. sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes); QTcF > 480 msecs based on Fredericia's formula or Bazette's formula; History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place; Uncontrolled hypertension as indicated by a minimum of 2 consecutive blood pressure measurements showing systolic blood pressure > 170 mmHg and diastolic blood pressure > 105 mm Hg; Cardiac event within 6 months of screening (e.g. coronary artery stent) requiring dual antiplatelet treatment
  • History of stroke or intracranial haemorrhage within 6 months prior to randomisation
  • Requires ongoing treatment with a strong CYP3A inhibitor or inducer
  • Inability to swallow oral medication
  • Concomitant treatment with another investigational agent
  • Autoimmune cytopenias
  • History of severe bleeding disorders considered not to be disease related (Haemophilia A, B or von Willebrand's disease)
  • Known infection with HIV, or serologic status reflecting active hepatitis B or C infection as follows:; Presence of hepatitis B surface antigen (HBsAg). In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the patient will be excluded; Presence of hepatitis C virus (HCV) antibody. Patients with presence of HCV antibody are eligible if HCV RNA is undetectable
  • Patients with chronic liver disease with hepatic impairment Child-Pugh class B or C
  • Known history of anaphylaxis following exposure to rat or mouse derived CDR-grafted humanised monoclonal antibodies
  • Disease significantly affecting gastrointestinal function and/or inhibiting small intestine absorption (e.g. malabsorption syndrome, resection of the small bowel, poorly controlled inflammatory bowel disease)
  • Active systemic infection requiring treatment
  • Any life-threatening illness, medical condition, organ system dysfunction, need for profound anticoagulation, or bleeding disorder, which, in the investigator's opinion, could compromise the patient's safety, or put the study at risk
  • History of prior malignancy, with the exception of the following:; Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to screening and felt to be at low risk for recurrence by treating physician; Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma, superficial bladder cancer, carcinoma in situ of the cervix or breast or localized Gleason score 6 prostate cancer without current evidence of disease
  • Lymphoplasmacytic lymphoma with no detectable serum IgM paraprotein
  • Renal failure (creatinine clearance <30 ml/min as estimated by the Cockroft-Gault equation)
  • CNS involvement with WM
  • Requires anticoagulation with warfarin or equivalent vitamin K antagonists (direct oral anticoagulants (DOACs) allowed)
  • Women who are pregnant or breastfeeding or males expecting to conceive or father children at any point from the start of treatment until the end of the "at risk period"
  • Unwilling or unable to take PCP prophylaxis (e.g. cotrimoxazole)

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Waldenström's macroglobulinaemia (WM) is a rare type of slow growing lymphoma. It develops when white blood cells grow abnormally.

A teljes eredeti leírásKevesebb

Typically a disease of the elderly, the median age of presentation is >70 years and the current treatment for WM is unsatisfactory, with incomplete responses and inevitable recurrence. Therefore there is a need to find alternative treatments that are more effective, leading to lasting responses and improved quality of life.

The RAINBOW study is a phase 2-3 trial assessing 'chemotherapy free' treatment as primary therapy for WM which can potentially improve response outcome, durability and importantly, reduce toxicity for WM patients. This approach will be done using the drug Ibrutinib, which in combination with rituximab (RI) will be the experimental arm. As there is no agreed standard on first-line therapy for WM, the control arm is the current treatment based on the most recently published clinical trial results. The control arm consists of rituximab, cyclophosphamide and dexamethasone (DCR), and is widely recommended by international consensus as appropriate treatment for first-line therapy for WM.

In this study, 148 adults (aged ≥ 18 years) with treatment naïve WM will be randomised on a 1:1 ratio to either the treatment or control arm.

Randomised treatment lasts for a maximum of 6 cycles and response will be assessed following 3 cycles of treatment and completion of randomised treatment at approximately 24 weeks after commencing treatment. RI patients may then have up to 5 years of Ibrutinib monotherapy.

Patients will be seen regularly during treatment and then every 3 months for 5 years after treatment discontinuation. Patients will enter annual follow up for survival until the end of trial (including progressed patients).

The study will be conducted at NHS hospitals and is expected to last 9 years and 6 months.

A vizsgálat 2 csoportja

  • DRC ArmMár használt kezelés, összehasonlításként

    The DRC arm (chemotherapy) is the control arm and consists of rituximab, cyclophosphamide and dexamethasone. It is widely recommended by international consensus as appropriate treatment for first-line therapy for WM.

    Kezelés: Dexamethasone, cyclophosphamide, rituximab

  • RI ArmA vizsgált kezelés

    The RI arm (chemotherapy free) arm will be using the drug ibrutinib, which in combination with rituximab (RI) will be the experimental arm.

    Kezelés: Rituximab, ibrutinib

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
A regiszteradat frissítve
2024. május 10.